^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Vulvar Cancer

    1d
    Immunohistochemical and serum profile of squamous cell carcinoma of the vulva: The Dual Vulvar Panel (DVP) project. (PubMed, Eur J Obstet Gynecol Reprod Biol)
    Serum SCC-Ag showed superior prognostic performance compared with individual IHC markers, and may be useful for postoperative risk stratification in VSCC. Combined biomarker panels, including p53, PD-L1, EGFR and p16, yielded promising sensitivity, supporting future strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53)
    |
    PD-L1 expression • EGFR expression
    3d
    Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer (clinicaltrials.gov)
    P2, N=25, Recruiting, Ohio State University Comprehensive Cancer Center
    New P2 trial
    3d
    Liquid Biopsy Analysis of the EV-Associated Micro-RNA Signature in Vulvar Carcinoma May Benefit Disease Diagnosis and Prognosis. (PubMed, Cancers (Basel))
    Multivariate Cox regression showed that a model of downregulated miR-16-5p and upregulated miR-451a was significantly associated with poorer survival (p = 0.023). This study indicates the future potential of exomiRs as diagnostic and prognostic liquid biopsy markers for vulvar cancer.
    Journal • Liquid biopsy
    |
    MIR143 (MicroRNA 143) • MIR16 (MicroRNA 16) • MIR223 (MicroRNA 223) • MIR451A (MicroRNA 451a)
    5d
    Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, University Hospital Tuebingen | Trial primary completion date: Apr 2025 --> Apr 2027
    Trial primary completion date
    7d
    Visualizing Cytoskeletal Protein Reconstruction of Vulvar Cancer with Surface-Enhanced Raman Spectroscopy and Gold Nanoparticles. (PubMed, ACS Omega)
    The three-dimensional Raman imaging of the cytoplasmic region of A431D cells exhibited unique features that combined the cytoarchitecture of A431 cells (parent cells expressing cytokeratins 8 and 18) and NIH 3T3 cells (used because they only express vimentin). This suggests that Raman imaging can be used to delineate cells that contain multiple types of intermediate filaments and serve as another method to identify cells undergoing EMT.
    Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin)
    10d
    TG4001.12: Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers (clinicaltrials.gov)
    P1/2, N=143, Active, not recruiting, Transgene | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Bavencio (avelumab) • tipapkinogene sovacivec (TG4001)
    12d
    Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, City of Hope Medical Center | N=126 --> 0 | Initiation date: Dec 2025 --> Jul 2026 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial initiation date • Trial withdrawal
    12d
    Unexpected Discovery of Myoepithelioma-Like Tumor of the Vulvar Region After Trauma: A Rare Case Report and Systematic Review of the Literature. (PubMed, J Cutan Pathol)
    These findings confirm the diagnosis of MELTVR. Although the biological behaviors of MELTVR remain incompletely understood, recognition of its characteristic morphologic and immunophenotypic profiles will aid in distinguishing it from potential histological mimics better.
    Journal
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • EWSR1 (EWS RNA Binding Protein 1) • CD34 (CD34 molecule) • VIM (Vimentin) • FUS (FUS RNA Binding Protein) • GFAP (Glial Fibrillary Acidic Protein)
    12d
    STRIVE: STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision (clinicaltrials.gov)
    P=N/A, N=249, Recruiting, British Columbia Cancer Agency | Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Nov 2031 | Trial primary completion date: Dec 2025 --> Nov 2031
    Enrollment open • Trial completion date • Trial primary completion date
    14d
    DOSTCONICG: The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological Cancer (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Cukurova University
    New trial
    15d
    [177Lu]Lu-AKIR001 First-in-human Study (clinicaltrials.gov)
    P1, N=15, Recruiting, Karolinska University Hospital | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF wild-type
    16d
    A Prospective Single-Arm Exploratory Study on CT-Based Radiomics Combined with Clinical Parameters for Predicting Lymph Node Metastasis in Gynecological Malignancies (Cervical, Ovarian, Endometrial and Vulval Cancers) (ChiCTR2500113585)
    P=N/A, N=350, Not yet recruiting, The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University
    New trial